Core Points - Gaming and Leisure Properties, Inc. (GLPI) declared a cash dividend of $0.78 per share for Q4 2025, payable on December 19, 2025, to shareholders of record on December 5, 2025 [1] - The current dividend reflects an annualized yield of 7.25%, based on a closing share price of $43.04 on November 21, 2025, compared to the previous year's Q4 dividend of $0.76 per share [1] Company Overview - GLPI is engaged in acquiring, financing, and owning real estate properties to be leased to gaming operators under triple-net lease arrangements, where tenants are responsible for all maintenance, insurance, taxes, and utilities related to the leased properties [3] - The company intends to pay regular quarterly cash dividends in the foreseeable future, with all subsequent dividends subject to quarterly review and declaration by the Board of Directors [2]

Core Viewpoint - Fury Gold Mines Limited has announced positive assay results from its inaugural drill campaign at the Sakami gold project, indicating significant gold mineralization and potential for future resource estimation [1][4]. Drilling Results - The 2025 diamond drill program completed 3,685 meters in seven holes, with six holes targeting extensions at La Pointe Extension and one hole at Juliette [1][9]. - Drill hole 25SK-005 intercepted 26.0 meters of 0.71 grams per tonne (g/t) gold, including 6.5 meters of 1.76 g/t gold [2][7]. - Drill hole 25SK-007 intercepted 22.2 meters of 0.83 g/t gold, including 2.9 meters of 1.71 g/t gold and 1 meter of 8.62 g/t gold [7]. Geological Insights - Drilling confirmed that mineralization at La Pointe Extension is open at depth and along strike to the west, improving continuity within previously identified gold mineralization [3][11]. - The mineralization occurs along a regional scale suture zone with numerous undrilled gold occurrences along 23.5 kilometers of strike within the Sakami property [7][8]. Future Exploration Potential - The drilling program has laid a foundation for future work, including potential mineral resource estimation [4][11]. - Regional soil sampling identified six structurally controlled gold anomalies for potential follow-up work, indicating further exploration opportunities [12]. Project Overview - The Sakami project covers approximately 14,250 hectares and is located in a prospective structural corridor between the Opinaca and La Grande Geological sub-provinces [8]. - Historical drilling has shown gold mineralization across widths of up to 75 meters and depths of up to 500 meters below the surface [9].

Core Insights - Waldencast plc reported a 5.6% year-over-year increase in net revenue for Q2 2025, reaching $66.8 million, with an Adjusted EBITDA Margin of 5.0% [2][10] - The company experienced contrasting performances across its brands, with Obagi Medical showing strong growth while Milk Makeup faced challenges in international markets [2][6] - Waldencast has updated its FY 2025 guidance to reflect current trends and investments aimed at long-term growth [1][8] Obagi Medical - Obagi Medical achieved double-digit net revenue growth in Q3 2025, driven by strong e-commerce and international market performance [3][19] - The brand is preparing for the launch of Obagi Saypha®, which will double its addressable market in the U.S. [3][4] - The sale of the Obagi Japan trademark for $82.5 million and credit facility refinancing has strengthened the company's balance sheet [5][8] Milk Makeup - Milk Makeup's net revenue for Q3 2025 was $25.2 million, a decline of 20.1% compared to Q3 2024, despite an 8% increase in U.S. consumption [20][23] - The brand's growth in the U.S. was supported by retail expansion and successful product launches, but international performance was weaker [6][20] - Transformation initiatives are being implemented to revitalize the brand, including team restructuring and increased investment in international markets [7][8] Financial Performance - For H1 2025, Waldencast's net revenue increased by 0.5% year-over-year to $132.3 million, with a net loss of $185.2 million primarily due to impairment charges [13][14] - Adjusted EBITDA for H1 2025 was $7.7 million, representing a margin of 5.8%, down from 13.4% in H1 2024 [15][16] - Q3 2025 net revenue decreased by 3.4% year-over-year to $67.8 million, with Obagi Medical contributing $42.6 million and Milk Makeup $25.2 million [18][23] Strategic Initiatives - Waldencast is conducting a strategic review to maximize shareholder value, having retained Lazard as a financial advisor [8][9] - The company is focused on building a leading dermatological megabrand at the intersection of skincare and medical aesthetics [4][5] - Continued investments in innovation, digital capabilities, and new distribution channels are expected to drive sustainable growth [25][24]

Core Insights - Kraken Robotics Inc. reported a significant revenue growth of 60% in Q3 2025, reaching $31.3 million compared to $19.6 million in the same quarter of the previous year, driven by strong demand in the defense sector and the acquisition of 3D at Depth Inc. [3][5] - The company achieved a gross margin of 59%, up from 52% year-over-year, reflecting a favorable revenue mix with higher-margin products and services [3][9]. - Adjusted EBITDA increased by 92% year-over-year to $8.0 million, resulting in an adjusted EBITDA margin of 25.5%, compared to 21.2% in the prior year [3][8]. Financial Performance - Consolidated revenue for Q3 2025 was $31.3 million, a 60% increase from $19.6 million in Q3 2024 [3][9]. - Product revenue rose by 46% to $18.3 million, while service revenue surged by 85% to $13.0 million, attributed to the growth in sub-bottom imaging services and the acquisition of 3D at Depth [3][9]. - Gross profit for the quarter was $18.6 million, an 81% increase from $10.3 million in the prior year, with a gross profit margin of 59% [3][9]. Capital Expenditures and Assets - Capital expenditures for the quarter were $6.3 million, significantly higher than $0.7 million in the comparable quarter, primarily for a new battery facility and internal marine assets [3]. - Total assets increased to $330.7 million as of September 30, 2025, compared to $101.2 million a year earlier, with cash reserves growing to $126.6 million from $14.9 million [3]. Guidance and Future Outlook - The company maintains its revenue guidance for 2025 between $120 million and $135 million, representing a 40% growth, and adjusted EBITDA guidance between $26 million and $34 million, indicating a 45% growth [3]. - Capital expenditure guidance has been raised to a range of $20.0 million to $21.0 million, reflecting increased investments in subsea power manufacturing facilities and internal marine assets [3].

Core Insights - Novo Nordisk announced top-line results from the phase 3 evoke and evoke+ trials for oral semaglutide in early-stage symptomatic Alzheimer's disease, involving 3,808 adults [1][2] - The trials did not show superiority of semaglutide over placebo in slowing Alzheimer's disease progression, despite improvements in biomarkers [2][4] - The decision to explore semaglutide for Alzheimer's was based on real-world evidence and previous studies, although the likelihood of success was considered low [4] Study Details - The evoke and evoke+ trials were randomized, double-blind, and placebo-controlled, focusing on patients aged 55-85 with mild cognitive impairment or mild dementia due to Alzheimer's [3][7] - Semaglutide was administered at a dose of 14 mg once daily, with a total of 1,855 and 1,953 participants randomized in the two trials respectively [7] - The primary measure of efficacy was the change in Clinical Dementia Rating – Sum of Boxes (CDR-SB) score from baseline to week 104 [6][7] Safety and Tolerability - Semaglutide demonstrated a safe and well-tolerated profile consistent with previous trials, with over 37 million patient-years of exposure across various populations [3][4] - The one-year extension period of the trials will be discontinued due to the lack of efficacy observed [4] Future Presentations - Topline results will be presented at the Clinical Trials in Alzheimer's Disease (CTAD) conference on December 3, 2025, with full results to follow at the 2026 Alzheimer's and Parkinson's Diseases Conferences in March 2026 [4]

Core Viewpoint - Comstock Inc. has received eligibility notifications for key environmental permits to establish an industrial-scale solar panel processing facility in Silver Springs, Nevada, which is crucial for the company's plans to recycle end-of-life solar panels and promote sustainable practices in the industry [1][2][3]. Regulatory Approvals - The company has obtained an Air Quality Permit and a Written Determination Permit from the Nevada Division of Environmental Protection, which are essential for the operation of a facility designed to process over 3 million solar panels annually, equating to approximately 100,000 tons of waste materials [2][3]. Facility Operations - The facility will utilize advanced technologies for the efficient processing and recycling of metal concentrates from photovoltaics, with equipment already ordered and expected to be delivered by the end of the year, allowing for installation and testing in early 2026 [2][3]. Market Position - Comstock Metals is positioned as a leader in the solar panel recycling market, particularly in the southwestern U.S., where many older solar panels are being decommissioned, thus increasing the demand for responsible recycling solutions [3][4]. Environmental Impact - The company emphasizes the importance of preventing heavy metal contamination from decommissioned solar panels, aiming to keep these materials out of landfills and avoid offshoring waste management issues [3][4]. Future Expansion - Comstock is strategically assessing additional processing and storage sites to capitalize on the growing demand for end-of-life solar panel recycling, reinforcing its market leadership and setting industry standards [4].

Core Insights - Linyi Trade City from Shandong province hosted a successful quality product expo in Ghana, leading to agreements worth 16.8 million yuan ($2.36 million) with five local enterprises [1] - The expo showcased a variety of building materials and products that cater to the needs of the Ghanaian market, attracting buyers from neighboring countries due to their high quality and affordability [2] - The event highlighted the potential for Linyi's products to fill gaps in the local market, particularly in the chemical products sector, which is currently inefficient in Ghana [3] Market Potential - The Linyi merchant delegation explored Accra and Tema, identifying opportunities for establishing overseas warehouses and integrating supply chains, indicating significant investment potential [4] - The delegation's visit to the Jinyi Industrial Park reinforced confidence in Linyi's expansion into West Africa, with local officials expressing eagerness for investment and collaboration [5] - Accra's government is prepared to assist Linyi enterprises in expanding their market presence, emphasizing a strong partnership [6]

Core Viewpoint - Scilex Holding Company has entered into a definitive agreement to exercise existing warrants, which is expected to generate approximately $20.3 million in gross proceeds for the company [1][4]. Group 1: Existing Warrants - The company will exercise a total of 428,572 shares from April 2024 Warrants at an exercise price of $38.50 per share and 475,824 shares from December 2024 Warrants at an exercise price of $22.72 per share [1]. - The aggregate gross proceeds from the exercise of these existing warrants are anticipated to be around $20.3 million before deducting fees and expenses [1]. Group 2: New Warrant Issuance - In exchange for the immediate cash exercise of the existing warrants, the company will issue a new unregistered warrant to purchase up to 1,356,594 shares of common stock at an exercise price of $29.00 per share [3]. - The new warrant will be exercisable immediately upon issuance and will have a term of five years [3]. Group 3: Use of Proceeds - The net proceeds from the offering are expected to be utilized for working capital and general corporate purposes [4]. Group 4: Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for treating acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [7][8]. - The company's commercial products include ZTlido, ELYXYB, and Gloperba, which target significant unmet medical needs [8][9].

Core Insights - Rakovina Therapeutics is advancing its AI-derived PARP-1 inhibitor program, showcasing progress at the 2025 Society for Neuro-Oncology Annual Meeting [1][5] - The company is utilizing AI methods to discover and characterize novel PARP1-selective small-molecule drug candidates that penetrate the central nervous system (CNS) [2][4] Research and Development - A scientific poster titled "Discovery and development of novel CNS-penetrating PARP1-selective inhibitors" was presented, highlighting collaboration with the Vancouver Prostate Centre and the University of British Columbia [2] - The research employs Deep Docking™ and generative-AI computational approaches to screen large chemical libraries for compounds with selective inhibition of PARP1 and favorable drug-like properties [3][4] Results and Data - Hundreds of prioritized compounds have been synthesized and evaluated, with a subset showing PARP1-selective activity and promising in vitro metabolic stability and pharmacokinetic profiles [4] - The presentation included comparisons of ADME and pharmacokinetic data from synthesized compounds against existing PARP inhibitors and next-generation benchmarks [4] Company Overview - Rakovina Therapeutics focuses on innovative cancer treatments, leveraging AI technologies like Deep-Docking™ and Enki™ to enhance drug candidate optimization [6] - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners [7]

VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Coppernico Metals Inc. (TSX: COPR, OTCQB: CPPMF, FSE: 9I3) (“Coppernico” or the “Company”), through its wholly owned private Peruvian subsidiary, Sombrero Minerales SAC, is pleased to announce that, having completed all required environmental studies, it has formally submitted an Environmental Impact Assessment – Semi-detailed ("EIA-Sd") drill permit application (the "Application") for its Sombrero Project in Peru. The permit, once granted, will ...